IRAK4 inhibiting agents

US11427561B2 · kind B2 · utility

Assignee

• Biogen MA Inc. · US

Inventors

• Timothy Chan · Cambridge, US
• Kevin M. Guckian · Northborough, US
• Tracy J. Jenkins · Watertown, US
• Jermaine Thomas · Chelsea, US
• Jeffrey Vessels · Marlborough, US
• Gnanasambandam Kumaravel · Westford, US
• Robert S. Meissner · Schwenksville, US
• Joseph P. Lyssikatos · South San Francisco, US
• Brian Lucas · San Francisco, US
• Irina Leaf · Cambridge, US
• Jeremy Duffield · Brookline, US
• Nathan Genung · Boston, US

Key dates

• Filing date: Jan 18, 2017
• Grant date: Aug 30, 2022
• Expiry date: Dec 30, 2039

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P37/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use and production. Formula (I) The compounds are IRAK-4 inhibitors useful for treating an inflammatory disease, an autoimmune disease, cancer, a cardiovascular disease, a disease of the central nervous system, a disease of the skin, an ophthalmic disease and condition, and a bone disease.